Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences (Nasdaq: RNA), a developer of Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in three major upcoming investor conferences in March 2025:
- TD Cowen 45th Annual Health Care Conference - March 4, 2025, at 3:10 p.m. ET
- Leerink Partners Global Healthcare Conference - March 11, 2025, at 1:00 p.m. ET
- Barclays 27th Annual Global Healthcare Conference - March 12, 2025, at 11:30 a.m. ET
The company will participate in fireside chats at each event. Live webcasts and archived replays will be available through Avidity's investor relations website.
Avidity Biosciences (Nasdaq: RNA), sviluppatore di Coniugati di Anticorpi Oligonucleotidici (AOCs™), ha annunciato la sua partecipazione a tre importanti conferenze per investitori che si terranno a marzo 2025:
- 45a Conferenza Annuale sulla Salute di TD Cowen - 4 marzo 2025, alle 15:10 ET
- Conferenza Globale sulla Salute di Leerink Partners - 11 marzo 2025, alle 13:00 ET
- 27a Conferenza Annuale Globale sulla Salute di Barclays - 12 marzo 2025, alle 11:30 ET
L'azienda parteciperà a discussioni informali in ciascun evento. Le trasmissioni in diretta e le registrazioni archiviate saranno disponibili sul sito web delle relazioni con gli investitori di Avidity.
Avidity Biosciences (Nasdaq: RNA), desarrollador de Conjugados de Anticuerpos Oligonucleotídicos (AOCs™), ha anunciado su participación en tres importantes conferencias para inversores que se llevarán a cabo en marzo de 2025:
- 45ª Conferencia Anual de Salud de TD Cowen - 4 de marzo de 2025, a las 3:10 p.m. ET
- Conferencia Global de Salud de Leerink Partners - 11 de marzo de 2025, a la 1:00 p.m. ET
- 27ª Conferencia Anual Global de Salud de Barclays - 12 de marzo de 2025, a las 11:30 a.m. ET
La empresa participará en charlas informales en cada evento. Las transmisiones en vivo y las repeticiones archivadas estarán disponibles a través del sitio web de relaciones con inversores de Avidity.
Avidity Biosciences (Nasdaq: RNA)는 항체 올리고뉴클레오타이드 접합체(AOCs™) 개발업체로, 2025년 3월에 열리는 세 가지 주요 투자자 회의에 참여한다고 발표했습니다:
- TD Cowen 제45회 연례 건강 관리 회의 - 2025년 3월 4일, 오후 3:10 ET
- Leerink Partners 글로벌 건강 관리 회의 - 2025년 3월 11일, 오후 1:00 ET
- Barclays 제27회 연례 글로벌 건강 관리 회의 - 2025년 3월 12일, 오전 11:30 ET
회사는 각 행사에서 비공식 대화에 참여할 예정입니다. Avidity의 투자자 관계 웹사이트를 통해 생중계 및 아카이브된 재생이 제공됩니다.
Avidity Biosciences (Nasdaq: RNA), développeur de Conjugués Anticorps-Oligonucléotides (AOCs™), a annoncé sa participation à trois grandes conférences pour investisseurs prévues en mars 2025 :
- 45e Conférence Annuelle de Santé de TD Cowen - 4 mars 2025, à 15h10 ET
- Conférence Mondiale de Santé de Leerink Partners - 11 mars 2025, à 13h00 ET
- 27e Conférence Annuelle Mondiale de Santé de Barclays - 12 mars 2025, à 11h30 ET
L'entreprise participera à des discussions informelles lors de chaque événement. Des webdiffusions en direct et des rediffusions archivées seront disponibles sur le site des relations investisseurs d'Avidity.
Avidity Biosciences (Nasdaq: RNA), Entwickler von Antikörper-Oligonukleotid-Konjugaten (AOCs™), hat seine Teilnahme an drei wichtigen Investorenkonferenzen im März 2025 angekündigt:
- 45. jährliche Gesundheitskonferenz von TD Cowen - 4. März 2025, um 15:10 Uhr ET
- Globale Gesundheitskonferenz von Leerink Partners - 11. März 2025, um 13:00 Uhr ET
- 27. jährliche globale Gesundheitskonferenz von Barclays - 12. März 2025, um 11:30 Uhr ET
Das Unternehmen wird an informellen Gesprächen bei jeder Veranstaltung teilnehmen. Live-Übertragungen und archivierte Wiederholungen sind über die Investor Relations-Website von Avidity verfügbar.
- None.
- None.
- TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 p.m. ET
- Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:00 p.m. ET
- Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 11:30 a.m. ET
Live webcasts of each event, up-to-date event details and archived replays will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in
Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-302382513.html
SOURCE Avidity Biosciences, Inc.
FAQ
When is Avidity Biosciences (RNA) presenting at the TD Cowen Healthcare Conference 2025?
Which investor conferences is Avidity Biosciences (RNA) attending in March 2025?
How can investors access Avidity Biosciences' (RNA) conference presentations?
What type of therapeutic technology does Avidity Biosciences (RNA) develop?
